.jpg)
STAT+: The business of CRISPR’d medicine: Not great
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
Category: Vertex
Vertex sues U.S. government over access to fertility support services for Casgevy patients
One of the makers of the Casgevy — the world’s first CRISPR-based medicine — filed a lawsuit…
STAT+: Vertex reports positive results in stem cell trial for type 1 diabetes
ORLANDO — Twelve people with type 1 diabetes who received a therapy derived from stem…
Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson
How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon? We…
STAT+: Vertex Pharmaceuticals is considering relocating its headquarters
When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that…
Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon
What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a…
STAT+: Can gene therapies make for a profitable business? Keep your eye on Bluebird Bio
Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy…
STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts
Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that…
STAT+: Vertex’s closely-watched pain relief drug succeeds in late-stage trials — with a catch
A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company…
No pain data yet from Vertex, and sky high deal expectations at JPM 2024
Want to stay on top of the science and politics driving biotech today? Sign up to…
After ‘SNL’ skit on sickle cell CRISPR therapy, advocates cite errors and stereotypes
Mary Brown was sipping coffee at home in Ontario, Calif., Sunday morning when a friend…
Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future
Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally…
STAT+: After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in
For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight…
STAT+: Inside Vertex’s decades-long quest to develop a new class of non-opioid painkillers
SAN DIEGO — For decades, the biotech industry has tried — and repeatedly failed —…
STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk
Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could…
STAT+: Vertex gets a win as Colorado board leaves cystic fibrosis drug off a list of unaffordable medicines
In a win for Vertex Pharmaceuticals, a Colorado state board voted not to place the…
STAT+: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough
Vertex Pharmaceuticals is being accused by a group of advocates and physicians of refusing to…
STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines
Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value…